Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

[News]

Amgen today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases.

More... (http://www.news-medical.net/news/20110628/Amgen-files-sBLA-for-XGEVA-with-FDA-to-treat-castrate-resistant-prostate-cancer.aspx)